We determined the AM22-52 binding epitope for the AM1 receptor extracellular domain using biophysical techniques, heteronuclear magnetic resonance spectroscopy and alanine scanning.
Introduction
Class B GPCRs are important drug targets, with their natural peptide ligands or mimetics being used to treat diseases, including diabetes and osteoporosis (Archbold et al., 2011) . Structural insights into peptide binding to these receptors gives guidance as to how the peptides could be modified and further improved for therapeutic purposes. Some class B GPCRs require receptor activity-modifying proteins (RAMPs) for high-affinity peptide interactions. The receptors for adrenomedullin (AM) and the related peptides calcitonin gene-related peptide (CGRP) and amylin belong to this category. The AM receptors are heteromers of the calcitonin receptor-like receptor (CLR) and RAMPs 2 or 3, which form the AM1 and AM2 receptors respectively (Poyner et al., 2002) . CLR with RAMP1 makes the CGRP receptor but this also has affinity for AM.
AM is a paracrine factor and is involved in the development of the lymphatic and blood vasculature (Hinson et al., 2000; Fritz-Six et al., 2008; Ichikawa-Shindo et al., 2008) . Embryonic lethality, thin blood vessel walls and significant defects observed in the vascular systems of AM, CLR and RAMP2 knock-out mice can be explained by abnormalities in the blood and lymphatic vasculature (Caron and Smithies, 2001; Dackor et al., 2006; Fritz-Six et al., 2008; Ichikawa-Shindo et al., 2008) . Inhibition of AM activity by its antagonist fragment AM22-52 can reduce vessel number and impede tumour growth (Ishikawa et al., 2003) . These data indicate that angiogenesis is induced by AM through the AM1 receptor, and that this receptor could be an attractive target for diseases characterized by insufficient or excessive angiogenesis.
There is as yet very little information on the structurefunction relationships of AM. In detergent micelles, AM exhibits negligible helical structure, although NMR analysis indicates that a helix is formed between residues 22 and 34, a finding that is corroborated by circular dichroism (CD) data (Robinson et al., 2009; Perez-Castells et al., 2012) . Chimeras of AM with related peptides indicated that its C-terminal 9 amino acids may be in proximity to RAMP3 in the AM2 receptor, but no similar data currently exist to indicate the specific regions of AM involved in its binding to the AM1 receptor (Robinson et al., 2009) .
Like other class B GPCRs, CLR is characterized by a large N-terminal extracellular domain (ECD) and seven transmembrane helices connected by intra-and extracellular loops and an intracellular C-terminal tail. Peptide binding to class B GPCRs is widely accepted to follow the twodomain model (Parthier et al., 2009 ). The C-terminus of the peptide binds to the large ECD through hydrophobic interactions, forming an a-helix. The receptor-activating N-terminus of the peptide can then dock into its binding pocket in the juxtamembrane region (the top of the TM and adjoining region of the extracellular loops) of the receptor. ECD crystal structures of CLR with RAMP1 and RAMP2 are now available, which reveal that despite its requirement for RAMP association, CLR shows high structural similarity to class B GPCRs, which do not require RAMPs to function (Grace et al., 2007; Parthier et al., 2007; Pioszak and Xu, 2008; Underwood et al., 2010a,b; Drechsler et al., 2011) . Nevertheless, the CLR/RAMP structures do not have peptide bound and there is clear evidence that RAMPs contribute to peptide binding Archbold et al., 2011) . Thus, the mode of binding of AM to its receptors remains to be determined. In this study, we sought to determine the regions of AM that are involved in binding to the AM1 receptor with a view to designing analogues of AM22-52 that exhibit increased affinity for the AM1 receptor.
Methods

Peptide synthesis
AM22-52 and its derivatives were synthesized using 9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide synthesis methodologies on a Tribute peptide synthesizer (Protein Technologies, Inc., Tucson, AZ, USA). The peptides were assembled on a 0.1 mmol scale using Aminomethyl ChemMatrix resin (PCAS Biomatrix Inc., Quebec, Canada) derived with the Fmoc-RINK linker (GL-Biochem, Shanghai, China) so as to afford a C-terminal amide on cleavage from the resin.
Fmoc deprotections were carried out by twice treating the resin with 3 mL of 20% piperidine (Sigma-Aldrich, St. Louis, MO, USA) in dimethylformamide (DMF) (Scharlau, Gillman, SA, Australia) for 5 min. For each coupling, 0.5 mmol of the Na-Fmoc-amino acid was dissolved in 2 mL of 0.23 M 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) (Peptides International Inc., Louisville, KY, USA) in DMF and added to the resin followed by 0.5 mL of 2 M N-methylmorpholine (Sigma-Aldrich) in DMF, and then allowing a reaction time of 40 min.
After its completion, the peptide was cleaved from the resin with concomitant removal of side chain-protecting groups by treatment with 10 mL of trifluoroacetic acid (TFA)/ 3,6-dioxa-1,8-octane-dithiol (DoDT)/H2O/triisopropylsilane (TIPS) (94:2.5:2.5:1 v/v) for 2 h at room temperature. After filtering, the peptide was precipitated from the filtrate by adding 40 mL of ice-cold ether and then pelleted by centrifugation. The supernatant was discarded and the pellet was washed well with chilled ether, air-dried, dissolved in water (15 mL), and lyophilized and stored at -30°C in siliconized microcentrifuge tubes.
AM22-52 labelled with 15 N and 13 C was also synthesized using Fmoc solid-phase synthesis. Labelled Fmoc-protected amino acids were purchased from Sigma-Aldrich and from Cambridge Isotope Laboratories (Andover, MA, USA). ChemMatrix aminomethyl resin was firstly derived with the Fmoc-Rink linker by treatment with a mixture composed of a 5-fold molar excess of the Fmoc-Rink acid, 5-fold molar excess of HBTU and 10-fold molar excess of diisopropylamine in DMF (acid concentration of 0.2 M). Synthesis of the peptide was carried out on a 0.025 mmol scale using this resin and a Tribute peptide synthesizer (Protein Technologies, Inc.). The iterative deprotectioncoupling procedure entailed firstly treatment of the resin with 20% (v/v) solution of piperidine in DMF, washing and then incubating with approximately 0.5 mL of a solution comprising 5 equivalents of Fmoc-amino acid (0.125 mmol), 5 equivalents of 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate and 10 equivalents of N-methylmorpholine in DMF for 1 h. Upon completion of the synthesis, the final Fmoc group was removed and the peptide was cleaved from the resin over 2 h using 5 mL of a mixture of TFA, DoDt, H2O and TIPS (94:2.5:2.5:1 v/v). The peptide was precipitated by diluting the TFA solution with 8 volumes of chilled diethyl ether, collected as a pellet by centrifugation, re-dissolved in 1:1 (v/v) acetonitrile/water and lyophilized.
Peptide purification and characterization
Unlabelled peptides were purified on a semi-preparative scale by RP-HPLC using the Dionex UltiMate® 3000 Binary Semipreparative system (Thermo Scientific, Sunnyvale, CA, USA). Samples were purified on a Gemini C-18 column (10 ¥ 250 mm, 5 mm, 110 Å; Phenomenex, Torrance, CA, USA) using 0.1% TFA/ultra-pure water as eluent A and 0.1% TFA/ acetonitrile as eluent B and generating a linear gradient of 0-30% B over 50 min at a flow rate of 5 mL·min -1
. The purified material was lyophilized for 72-96 h and stored at -30°C in siliconized microcentrifuge tubes.
The identity of the purified products was confirmed by ion-spray MS on a Thermo Finnigan Surveyor MSQ Plus spectrometer (Thermo Electron Corporation, Waltham, MA, USA). Analytical RP-HPLC was performed on a Gemini C-18 column (4.6 ¥ 250 mm, 5 mm, 110 Å; Phenomenex) on a linear gradient of 0-50% buffer B over 60 min at a flow rate of 1 mL·min -1 , with UV absorbance monitored at 210 nm. The integration of the HPLC chromatograms at 210 nm indicated a purity of at least 90%. Amino acid analyses were performed by the Australian Proteome Analysis Facility Ltd. For assays, peptides were dissolved in water to a concentration of 1 mM, accounting for peptide content and stored as aliquots at -30°C in siliconized microcentrifuge tubes.
Purification of labelled AM22-52 was carried out by RP-HPLC, in which 1 mL aliquots of a 8 mg·mL -1 aqueous solution of the peptide was loaded onto a Jupiter Proteo 4 mm 90 Å, 10 ¥ 250 mm column (Phenomenex) and eluted with a gradient of 1-31% buffer B over 60 min. The resulting peptide is referred to as 13 C/ 15 N-AM22-52.
Cell culture and transfection
Culture of Cos-7 cells was performed as previously described (Bailey and Hay, 2006) . Cells were cultured in DMEM supplemented with 8% heat inactivated FBS and 5% (v/v) penicillin/ streptomycin and kept in a 37°C humidified 95% air/5%CO2 incubator. Cells were seeded into 96 well plates at a density of 10 000 cells per well (determined using Countess Counter™; Life Technologies, Carlsbad, CA, USA) 1 day prior to transfection. Cells were transiently transfected using polyethylenimine as described previously (Bailey and Hay, 2006) using full-length HA-tagged CLR and full-length untagged RAMP1, 2 or 3 constructs. These combinations generated human CGRP, AM1 and AM2 receptors respectively. This nomenclature conforms to the British Journal of Pharmacology's Guide to Receptors and Channels (Alexander et al., 2011) .
cAMP assays cAMP assays were performed as previously described (Gingell et al., 2010) . On the day of the assay, cells were serumdeprived in 50 mL per well DMEM containing 1 mM 3-isobutyl-1-methylxanthine and 0.1% BSA for 30 min. Fulllength human AM (American Peptide, Sunnyvale, CA, USA), reconstituted to 1 mM in ultra-pure water, was diluted in the same medium to give a final concentration range of 1 pM-1 mM. This material was added (25 mL per well), in the absence or presence of AM22-52 (25 mL per well), and incubated at 37°C for 15 min. Forskolin (50 mM) (Tocris Bioscience, Bristol, UK) was included as a positive control on each plate. Pre-incubation with AM22-52 for up to 30 min did not affect our antagonist potency estimates (data not shown). After incubation, the contents of the wells were aspirated and cAMP was extracted by adding 50 mL of lysis buffer as per the AlphaScreen protocol (PerkinElmer, Boston, MA, USA). The plates were gently shaken at room temperature for 15 min. A cAMP standard curve was generated from the kit cAMP standard (AlphaScreen cAMP assay kit; PerkinElmer) in the range of 100 pM-2.6 mM, 10 mL per well and was added to a white 384-well opti-plate (PerkinElmer). Ten microliters of each cell lysate was transferred to the plate. Five microliters of acceptor beads (1:100 dilution in lysis buffer) was added to each well, the plate was sealed and incubated in the dark for 30 min at room temperature. Five microliters of the donor bead mix (1:100 dilution of donor beads and biotinylated cAMP in the lysis buffer) was added to all wells; the plate was resealed and incubated in the dark for 6 h. The plates were read using an Envision plate reader (AlphaScreen protocol; PerkinElmer). The quantity of cAMP produced was determined from the raw data using the cAMP standard curve. A comparison of AM (American Peptide) and in-house synthesized AM22-52 was carried out to confirm that there was no difference between these peptides (data not shown). 13 C/ 15 N-AM22-52 was also compared and behaved equivalently to unlabelled peptide (Table 2) .
Data analysis and statistical procedures for cAMP assay data
Data analysis, statistical interpretation, curve fitting and graphing were undertaken using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA). The data from each concentration-response curve were fitted to a sigmoidal curve using a four-parameter logistic equation in order to calculate the maximum response (Emax) and the log EC50 values, with a Hill slope of 1, after first comparing fits by F-test. For calculation of antagonist potency values (pA2), agonist concentration-response curves were fitted in the absence or presence of antagonist and analysed by global Schild analysis as previously described (Hay et al., 2005) . AM22-52 is a competitive antagonist (Hay et al., 2003) ; Schild slopes were not significantly different to one and were therefore constrained to one to derive antagonist potency estimates. Statistical analysis was carried out by one-way ANOVA followed by Dunnett's test, and the significance was accepted at P < 0.05. Data are presented graphically as the mean of normalized data; in each experiment, data were normalized to the maximal AM response. and RAMP2 (36-144) constructs were constructed as previously described and encoded an N-terminal hexahistidine tag and Tobacco Etch Virus cleavage site on the RAMP2 construct. Expression in Escherichia coli Rosetta 2 cells was carried out at 37°C with induction at OD600 nm of 0.6 for 3 h at a final concentration of isopropyl thiogalactopyranoside of 0.5 mM. Bacteria were harvested by centrifugation and inclusion bodies isolated as previously described . Twenty milligrams of both CLR and RAMP2 inclusion bodies were added to 100 mL of 8 M urea (pH 8.0) and co-refolded against refolding buffer [20 mM Tris-HCl (pH 8.0), 500 mM L-arginine, 1 mM EDTA, 5 mM reduced glutathione, 1 mM oxidized glutathione] for 50 h at 4°C. Arginine was removed by further dialysis (12 h, 4°C) against dialysis buffer [20 mM Tris (pH 8.0), 1 mM EDTA, 10% glycerol, 50 mM NaCl] with a further change of this buffer 12 h later. Purification by ion exchange and gel filtration chromatography was carried out as previously described . We refer to the resulting complex as the AM1 receptor ECD. The components of the AM1 receptor complex were digested with trypsin (Promega, Madison, WI, USA) and then analysed by reversed-phase LC-MS/MS on a QSTAR XL (AB Sciex, Foster City, CA, USA). Matches with cloned sequences were identified using Mascot v2.0.05 software (Matrix Science, London, UK) and by manual interpretation of some spectra representing modified sequences. Peptide peak areas were integrated using the LC-MS Reconstruct tool within Analyst QS1.1 software (AB Sciex).
Recombinant protein expression and purification
Analytical gel filtration
Analytical gel filtration was carried out using a Superdex 75 10/300 GL column (GE Healthcare, Buckinghamshire, UK) and low MW standards (Sigma-Aldrich) of 66, 29, 12.4 and 6.5 kDa. In addition, 0.5 mL of purified AM1 receptor ECD, CLR and MW standards were loaded onto the column as separate runs in gel filtration buffer.
Isothermal titration calorimetry (ITC)
ITC was undertaken on a MicroCal ITC titration calorimeter (MicroCal Inc., Northampton, MA, USA). All experiments were carried out in duplicate. The reaction cell contained purified AM1 receptor ECD in the gel filtration buffer [20 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 10% glycerol] at 30 mM, degassed at 1/3 atm for 10 min. AM22-52 or its analogues were dissolved in the gel filtration buffer to 300 mM and similarly degassed. The peptide was titrated into the cell over 27 titrations of 10 mL at 400 s intervals. The experiment was carried out at 25°C and a stirring speed of 307 r.p.m. Heats of dilution were determined from control titrations; peptide was injected into buffer or buffer injected into AM1 receptor under the same conditions. The heat generated per injection was obtained by numerical integration of the raw data. Heats of dilution were subtracted from the observed heats of binding before model fitting and parameter calculation. A one set of sites binding model was used, from which the dissociation constant (Kd), the enthalpy and entropy of binding (H and S, respectively) and the binding stoichiometry were calculated.
CD spectroscopy
CD measurements were carried out as previously described (Robinson et al., 2009 ) using a p-Star 180 spectrometer (Applied Photophysics, Leatherhead, UK). CD spectra for AM22-52 or its analogues in 50% trifluoroethanol (TFE) at 50 mM were collected from 260 to 180 nm at 1 nm intervals with a bandwidth of 1 nm and a data collection time of 1 s at each wavelength under nitrogen gas. An average of five spectra was taken and baseline data for 50% TFE alone were subtracted to give absolute CD values. Molar ellipticity values for these spectra were calculated and analysed for secondary structure content using the K2D program (Andrade et al., 1993) . (Grzesiek and Bax, 1993) . The data matrix consisted of 128* ¥ 1024* data points (where n* refers to complex points) with acquisition times of 72.6 (tN) and 136.4 ms (tHN). The recycle delay was 1.1 s, with eight transients per increment. The total experimental time was 20 min.
NMR sample preparation
15
N decoupling was applied during data acquisition.
13 C decoupling was achieved using an adiabatic pulse placed in the centre of the tN period. Proton chemical shifts were referenced to TSP, whereas the 15 N and 13 C chemical shifts were indirectly referenced according to the ratios given by Wishart et al. (1995) .
The triple resonance three-dimensional (3D) spectra [CBCANH, CBCA(CO)NH, HNCA] were recorded as constanttime water flip-back experiments (Grzesiek and Bax, 1992a,b; . The CBCANH and CBCA(CO)NH data matrices consisted of 70*(t1) ¥ 37*(t2) ¥ 1024*(t3) data points, with acquisition times of 6.6, 21.7 and 136.4 ms respectively. The total acquisition time for each experiment was 16 h. The 3D HNCA data matrix consisted of 55*(t1) ¥ 35*(t2) ¥ 1024*(t3) data points, with acquisition times of 11.4, 19.8 and 136.4 ms respectively. The total acquisition time was 48 h. The 13 C carrier was positioned at 53 p.p.m. in the 3D experiments. Datasets were processed using NMRPipe (Delaglio et al., 1995) and analysed with CcpNmr analysis (Vranken et al., 2005) .
Chemical shift perturbation
For analysis of the backbone 1 H N and 15 N chemical shift perturbations, a weighed average chemical shift change was calculated using the following equation (Grzesiek et al., 1996) 
Results
Isolation of the AM 1 receptor ECD
Co-refolding of CLR (23-133) and RAMP2 (36-144) into 500 mM arginine from 8 M urea proceeded with no precipi-tate visible after 50 h of dialysis; a small amount of precipitation occurred upon removal of arginine by dialysis into the dialysis buffer. This may have been due to impurities in the inclusion body preparations. Anion exchange and gel filtration chromatography yielded a stable receptor ECD complex that co-eluted as a single peak after both chromatography processes ( Figure 1A ). Functional folding and complex formation of the AM1 receptor ECD was confirmed by ITC, which gave a Kd of 5 mM for AM22-52 ( Figure 1B) . The data also confirmed the presence of a single AM1 receptor binding site for the AM22-52 peptide. Analytical gel filtration of the AM1 receptor ECD at a concentration of 0.5 mg·mL -1 revealed a single peak eluting at a volume corresponding to a MW of 46.5 kDa. The expected MW of the AM1 receptor heterodimer is 29.4 kDa, composed of the 16.3 kDa RAMP2 and 13.1 kDa CLR molecules ( Figure 1C ). Protein complex digestion and LC-MS/MS followed by searching against the predicted fragments for CLR and RAMP2 using the Mascot software yielded a positive identification for the peptides. Peak integration of the LC-MS/MS data of the peptide fragments revealed a 1.5:1 ratio of CLR to RAMP2 ( Figure 1C ). This indicates the presence of a CLR homodimer and a RAMP2 monomer in the AM1 receptor complex. A complex with this stoichiometry would have an expected MW of 42.5 kDa. This corresponds to a MW of 46.5 kDa observed by analytical gel filtration chromatography.
Identification of the AM 1 receptor epitope of AM 22-52
We undertook solution-state NMR studies on 13 C/ 15 N AM22-52 to identify key residues located at the binding interface between the AM1 receptor ECD and the peptide. The 2D 1 H-15 N HSQC spectrum of apo-AM22-52 is presented in Figure 2A . The sequence-specific 1 H-15 N assignments of apo-AM22-52 were derived from 3D CBCANH and CBCA(CO)NH experiments, and resonances are labelled with assignment information. Chemical shift indexing with the 1 HN, 1 Ha, 13 Ca and 13 Cb chemical shifts indicated that there was no apparent secondary structure present in the apo-form of AM22-52 (Supporting Information Figure S1 , Table S2 ). However, a distinct linear epitope was evident at the C terminus of the peptide (Supporting Information Figure S1 ). The uniform incorporation of 13 C and 15 N into the synthetic AM22-52 peptide facilitated backbone resonance assignment of AM22-52 in complex with the AM1 receptor ECD (Figure 2A ). To achieve backbone resonance assignment of the peptide complex with the receptor, a 3D HNCA spectrum was used in conjunction with the available assignment information of the apo-peptide. Although all backbone 1 H N and 15 N resonances were assigned for AM22-52 in the free form, assignments for residues Q24, I47 and Y52 were not assigned in the peptide-receptor complex. For these residues, resonances were either not visible or significantly line-broadened in the 2D 1 H-15 N HSQC spectrum, indicative of chemical exchange broadening resulting from flexibility on the microsecond to millisecond timescale. In addition, resonances for residues Y31, Q32, F33, T34, N40, V41, A42, R44 and G51 were weak and were only observed at low contour levels (resonance frequencies are depicted as dashed circles in Figure 2A ). These resonances are likely to be affected by chemical exchange, therefore leading to a reduction in signal intensity.
The 2D 1 H-15 N HSQC for AM22-52 in complex with the AM1 receptor ECD shows the same resonance dispersion as observed in the spectrum of the free form (Figure 2A ). Significant differences in linewidths and chemical shift perturbations were observed upon complex formation. A qualitative analysis of the chemical shift perturbation was performed using the normalized Figure 2B ). Residues located in the N-terminal segment (i.e. residues 24-44) showed a significantly smaller average chemical shift perturbation (0.0170 Ϯ 0.0004 p.p.m.), indicating that these residues are not at the key binding interface and the small changes reflect subtle conformational rearrangements being transmitted through the peptide to facilitate binding to the receptor. Unfortunately, due to missing assignment information, chemical shift perturbations could not be obtained for residues Q24, I47 and Y52. The chemical shift mapping results clearly indicate that the C-terminal segment of AM22-52 is a major AM1 receptor ECD binding epitope.
Alanine substitution of AM 22-52 residues 44-52
To investigate and characterize the roles of the individual amino acids constituting this major AM1 receptor ECD binding epitope of AM22-52, each residue in this region was individually replaced with alanine. Two complementary methods were used to determine the impact of these substitutions: binding affinities of these peptides were determined by ITC at the AM1 receptor ECD and in functional assays at the full-length AM1, AM2 and CGRP receptors.
All ITC experiments were carried out at a concentration of 30 mM AM1 receptor ECD, with a 10-fold excess of peptide. The measurements for each peptide were carried out in duplicate using a different preparation of AM1 receptor ECD for each experiment. Y52A, G51A and I47A AM22-52 completely abolished binding to the AM1 receptor ECD (Table 1) , indicating that these residues are intrinsically involved in AM22-52 binding to the AM1 receptor. K46A AM22-52 resulted in a 10-fold decrease in binding affinity. Small changes in binding affinity were seen for Q50A, P49A, S48A and R44A AM22-52. The chemical shift changes seen in the NMR HSQC experiments for these residues may be due to a change in their molecular environment because of their increased proximity to the AM1 receptor ECD. This change in environment could also be due to a structural change within the peptide occurring upon its binding to the receptor.
The binding affinity of AM22-52 at 37°C was determined in the same manner as that measured at 25°C and showed a decrease in binding affinity to 29 mM. The enthalpy change became more negative at -31.4 kcal·mol -1 when the experiment was conducted at 37°C, indicating that the AM22-52-AM1 receptor ECD interaction is predominantly through hydrophobic interactions.
Affinities of alanine-substituted peptides were also determined at the full-length AM1 receptor transfected into Cos-7 cells. AM22-52 behaves as an antagonist of AM-stimulated cAMP production. The ability of each peptide to antagonize the receptor was compared to AM22-52 (Table 2) . Y52A, G51A and I47A AM22-52 resulted in Ն100-fold reduction in antagonist potency compared to AM22-52. R44A, K46A, S48A and P49A AM22-52 decreased antagonist potency by approximately 10-fold, whereas S45A and Q50A AM22-52 showed no significant alteration (Figure 3) . A peptide comprising only the C-terminal 9 amino acids (9-mer) had no detectable affinity.
AM and thus its AM22-52 fragment can also bind to the CGRP and AM2 receptors. To determine if these same residues are also important for binding in the presence of a different RAMP, Cos-7 cells were transfected with CLR and RAMP1 (CGRP receptor) or CLR and RAMP3 (AM2 receptor). Similar patterns were observed for most peptides at both receptors (Table 2 ). P49A AM22-52 did not, however, lose affinity at the CGRP receptor and R44A AM22-52 only lost affinity at the AM1 receptor.
CD spectroscopy of AM 22-52 and its alanine analogues
CD was carried out on AM22-52, its analogues and the isolated C-terminus in order to establish that any functional change observed was not due to a change in the intrinsic structure of the peptide upon modification. No significant change in the relative proportions of a-helix or b-sheet was observed upon the introduction of the alanine substitutions (Table 3) . On the other hand, the 9-mer had no secondary structure in 50% TFE.
Discussion
The ECD of the AM1 receptor was successfully refolded and purified from its constituent RAMP2 and CLR ECDs. Analytical gel filtration yielded a MW of 46.5 kDa for the purified receptor ECD. Together with the MS data, this value indicates a stoichiometry of two CLR molecules to one RAMP2 molecule. When refolded and purified in the absence of the RAMP2 molecule, the CLR ECD shows obvious oligomerization with elution peaks corresponding to a single CLR at 13.3 and a multimer at 69.8 kDa. Recent crystal structures of the CGRP and AM1 receptor (ter Haar et al., 2010; Kusano et al., 2012) indicate that the ECD of these receptor complexes exhibit a 1:1 stoichiometry of their CLR : RAMP components. These structures were solved using shortened fragments of both CLR and RAMP1 or 2 of varying length, selected for by their propensity to crystallize. Indeed, the AM1 receptor structure used a RAMP2 fragment significantly Table 1 Isothermal titration calorimetry for AM22-52 and alanine analogues of the C-terminal nine residues of AM22-52 at the AM1 receptor ECD
Peptide
Kd (mM) Values shown are the mean of two values (n = 2); in no case does the error exceed 17% of the value indicated. No binding indicates that no value was measurable due to the low affinity of the peptide-receptor interaction. -denotes an immeasurable value due to the low affinity binding and thus inaccuracy of these measurements.
shorter than that used in this study. This may have selected for fragments which form a 1:1 stoichiometric complex. The asymmetric unit of the AM1 receptor contains a dimer of the heterodimer AM1 receptor complex in which hydrogen bonding has been observed between the two CLR molecules. It may be the case that the 46.5 kDa MW observed in analytical gel filtration in this study corresponds to a dimer of the AM 1 receptor heterodimer, as seen in the AM1 receptor structure (Kusano et al., 2012) , although this would seem unlikely given the ratio of approximately 1.5:1 CLR : RAMP2 observed by MS. This non-integer ratio is most likely due to a lower molar response on average for the population of peptides representing one protein over the other; however, it nevertheless indicates a significantly higher proportion of CLR, and taken together with the apparent MW of the complex as observed by analytical gel filtration, supports a 2:1 stoichiometric ratio of CLR : RAMP2 over any other hypothesis. It is worth considering that in both crystal structures and this study, the ECD is not in its full-length physiological form and thus not subject to spatial constraints that would be present in the full-length receptors. Investigations on the oligomerization of the full-length CGRP receptor report a stoichiometry of a CLR homo-oligomer and a RAMP1 monomer, consistent with our observations for CLR and RAMP2 (Heroux et al., 2007) . Irrespective of the actual stoichiometry, the purified AM1 receptor ECD was capable of binding AM22-52 with a Kd of 5 mM. Binding studies of various peptide fragments to their receptors have been carried out using both ITC and surface plasmon resonance (Parthier et al., 2007; Pioszak and Xu, 2008; Koth et al., 2010; Drechsler et al., 2011; Kusano et al., 2012) . Depending on the receptor and the methodology used, the binding affinities of these peptide fragments to their receptor ECDs vary across the milli-to nanomolar ranges but are predominantly in the low micromolar range. Therefore, the Kd we observed for AM22-52 is in-line with expectations from this literature. In the two-domain model of peptide ligand binding to this class of GPCR (Parthier et al., 2009) , the peptide C-terminus binds to the ECD and the peptide N-terminus binds to the receptor transmembrane bundle and extracellular loops. Thus, the affinities determined by ITC are likely to be lower when not all points of contact with the receptor are available for that particular peptide. For AM22-52, the lower affinity at the ECD in ITC compared with the full-length receptor in the cAMP assay could suggest that AM22-52 may be making contact with parts of the receptor other than the ECD. However, differences in these assays make it difficult to directly compare values. It would be interesting to compare the affinities of different lengths of AM between the two assays.
In solution-state NMR studies, we were able to assign backbone resonances for both the apo and receptor bound forms of AM22-52. Only a small number of resonances underwent large chemical shift changes when AM22-52 was mixed with the AM1 receptor ECD. Nonetheless, we observed significant differences in both linewidths and chemical shift perturbations for a number of residues upon complex formation. Resonances arising from G51, Q50, S48, K46 and S45 showed a weighed chemical shift perturbation greater than the average plus 1 SD (0.15 p.p.m.), which was significantly larger than those observed for the remainder of the molecule. Assignments for I47, Y52 and Q24 were not made. These omissions notwithstanding, we can clearly locate the major AM1 receptor ECD binding epitope of AM22-52 to the last eight residues at the C-terminus of the peptide. Guided by these NMR results and previous studies by Robinson et al. (2009) , which implicated these amino acids of AM22-52 in binding to the AM2 receptor, we made progressive alanine substitutions of the C-terminal amino acid residues of AM22-52. Characterization of these peptides in ITC and functional assays further pin-pointed residues Y52, G51, I47 and K46 as essential for high-affinity receptor interactions. Each of these substitutions resulted in substantial reductions in binding affinity to the AM1 receptor ECD and full-length receptor. CD spectroscopy indicated that there was no major structural perturbation to these peptides. This allows us to infer that these residues are present at the AM1 receptor binding interface and may be forming discrete interactions with the receptor ECD. Previous structure-activity studies have shown that both Y52 and the C-terminal amide group characteristic of many class B GPCR peptide ligands are essential for AM binding to its full-length receptor, although they appear to have discrete roles in this process (Eguchi et al., 1994) .
The chemical shift perturbations observed for the remaining residues in the C-terminal binding epitope determined by NMR (e.g. S45, Q50) may be due to the proximity of these residues to the binding cleft or a change in peptide structure as it binds to the receptor ECD. Thermodynamic data can give us no information on the exact nature or number of these potential interactions. The increase in negativity of the Table 2 pA2 values of antagonist potency for AM22-52 and alanine analogues of the C-terminal amino acids at full-length receptors, generated in cAMP assays R44A AM22-52 6.89 Ϯ 0.07** (n = 3) 7.37 Ϯ 0.18 (n = 4) 5.64 Ϯ 0.18 (n = 4)
Error is presented as the SEM. *P < 0.05; **P < 0.01; ***P < 0.001 versus AM22-52 by one-way ANOVA, followed by Dunnett's multiple comparison test. Peptide did not produce a measurable shift in the AM concentration-response curve in a further experiment; therefore, a pA2 value could not be determined for that occasion. ND, not done.
Table 3
Relative percentages of secondary structural elements for AM22-52 and alanine substitutions of the C-terminal nine amino acids as determined by circular dichroism spectroscopy Circular dichroism data were deconvoluted using the online web server K2D. These values should be used with caution; analysis using different programmes yields varying percentages and, therefore, these values are only useful for comparing between peptides and not necessarily between studies.
Figure 3
Concentration-response curves for the alanine mutants of AM22-52 at the AM1 receptor. Cos-7 cells were transfected with HA tagged CLR and untagged RAMP2 and assayed for human AM-stimulated cAMP response. Curves are plotted as a percentage of the maximal human AM-stimulated cAMP production. Each figure shows combined data from three to five independent experiments, which were each performed in triplicate. Each point on the graphs represents the mean Ϯ SEM. Due to the different affinities of the peptides, different concentrations were used, up to the possible maximum for that peptide in order to obtain shifts.
DH values at 37°C compared with those at 25°C does, however, indicate that the binding interactions are of a mainly hydrophobic nature. This would be consistent with the accepted mode of binding of peptides to other class B GPCRs (Parthier et al., 2009) . At the AM2 receptor, the same residues appear to have a significant involvement in functional antagonist activity as we observed at the AM1 receptor. Antagonist activities at the CGRP receptor were very low, meaning that any decrease in these due to the effect of alanine substitutions resulted in a complete abolition of antagonist activity detectable by our system. R44A AM22-52 showed a selective decrease in affinity at the AM1 receptor and also showed a threefold decrease in Kd at the AM1 receptor ECD as determined by ITC. This may be a RAMP2-dependent residue. When it becomes possible to solve peptide bound structures of the AM1 and AM2 receptors, it will be interesting to see what contribution this residue makes to binding. Surprisingly, R44 did not show a substantial chemical shift perturbation when the peptide was mixed with the receptor. The reason for this discrepancy is unclear.
Interestingly, the 9-mer fragment comprising only the last nine amino acids of AM22-52 had no measurable affinity. On the other hand, it appears unstructured in CD analysis and this may explain its lack of activity. Other portions of the peptide may be required to stabilize the conformation of this region needed for binding. Indeed, we observed small chemical shifts for the residues Q24-T34 of AM22-52, indicating that these also have a functional role to play in the peptide (Eguchi et al., 1994; Robinson et al., 2009) . Future studies could seek to stabilize C-terminal fragments of varying length, based on our observations of the importance of this region.
Although many crystal structures of class B GPCRs are now available, most have only short peptide fragments bound and few encompass the extreme C-terminus. The recent structure of the AM1 receptor ECD does not have peptide bound, although it does indicate some residues in the receptor that may be involved in AM binding (Kusano et al., 2012) . Existing NMR structures of AM (Perez-Castells et al., 2012) and AM22-52 (Supporting Information Figure S2 ) are not suitable for docking into the receptor crystal structure. Those other class B GPCR structures that do include the C-terminal region of peptide fragments indicate that peptide residues involved in receptor binding are situated towards the middle of the peptide rather than at the extreme C-terminus (Parthier et al., 2007; Underwood et al., 2010a,b) . However, alanine scanning has implicated residues closer to the C-terminus of other class B peptide ligands in receptor binding (Lang et al., 2006; Grace et al., 2007; Pioszak and Xu, 2008; Dong et al., 2011) . In particular, amino acid substitutions within a C-terminal 10-mer of CGRP showed antagonist activity in the nanomolar range (Rist et al., 1998) . Substitution, the enhancement of b-turns and cyclization by disulphide bond formation of this 10-mer peptide resulted in antagonists with even higher picomolar affinity for the CGRP receptor (Lang et al., 2006; Yan et al., 2011) . Therefore, the importance of the extreme peptide C-terminus may be a particular feature of the AM and CGRP receptors. This may correlate with the requirement for RAMPs in high affinity binding; the recent structure would certainly indicate a shift in binding pocket if RAMP2 is directly involved in AM binding (Kusano et al., 2012) .
In this study, we have pin-pointed a discrete AM epitope between residues R44 and Y52, which is involved in binding to the AM1 receptor. We have defined the precise residues of AM22-52, which are involved in binding to the AM1 receptor and the role that they play within the binding epitope. This complements structural studies of the receptor, although more constraints are required to allow accurate docking of AM into the receptor. Our study provides useful information with which to pursue the development of high affinity antagonist analogues of AM22-52.
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Figure S1 Stereo view representation of the 15 lowest energy solution structures of the AM22-52 peptide. The amino terminus is show in dark blue, whereas the carboxy terminus is on the opposite side and shown in brown/green.
Figure S2
Overview of AM structures for residues 22-52 in solution (left) and in the presence of SDS micelles (right). Residues with elevated values from the chemical shift mapping are coloured in red (S45, K46, S48, Q50, G51). Table S1 NMR data acquired on AM22-52. 
